crystal form O with other crystal forms exist in 3423+/-5cm^{-1}, 3310+/-5cm^{-1}, 3193+/-5cm^{-1}, 2980+/-5cm^{-1}, 2470+/-5cm^{-1}, 1693+/-2cm^{-1}, 1167+/-2cm^{-1}, 1023+/-2cm^{-1} and 603+/-2cm^{-1}.

4. The Aildenafil citrate crystal form O according to claim 1, wherein, a determination result of a thermal analyzer shows that a sample does not contain a crystalline solvent.

5. A preparation method of the Aildenafil citrate crystal form O according to any one of claims 1 to 4, wherein, the Aildenafil citrate crystal form O can be obtained through the steps of: dissolving the Aildenafil citrate in 25 to 26 times (weight-volume ratio, g/ml) of mixture of distilled water and tetrahydrofuran, stirring, heating to reach the backflow temperature, filtering after 15min to 20min while heating, cooling a filtrate to be the room temperature by stirring, insulating heat and stirring for 24h to 26h, precipitating and crystallizing, filtering and drying.

6. The preparation method of the Aildenafil citrate crystal form O according to claim 5, wherein, in the mixture of the distilled water and the tetrahydrofuran, the tetrahydrofuran takes 5% to 15% of the volume of the mixture.

7. A composition formed by the Aildenafil citrate crystal form O according to any one of claims 1 to 4 with one or more pharmaceutically acceptable carriers, excipients or diluents.

8. The composition of the Aildenafil citrate crystal form O according to claim 7, wherein the composition is used for preparing oral preparations.

9. The composition of the Aildenafil citrate crystal form O according to claim 8, wherein, the pharmaceutical composition is applied in preparing drugs for treating Male Erectile Dysfunction (ED).